Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — April 2026

Genmab — April 2026

Planlagt Fastgjort Låst Flyttet Genmab
133 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #47

    posters/presentations at SGO Annual Meeting on April 10-13, 2026 via https://www.genmabmedicalaffairs.com/congress?filv1=28

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #48

      that'
      s on rinatabart and tisotumab

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #49

        Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study https://www.sciencedirect.com/science/article/pii/S0090825826008012

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #50

          Godmorgen 🙂

          1 Reply Last reply
          0
          • L Offline
            L Offline
            LP90
            wrote on sidst redigeret af
            #51

            Godmorgen 🙂

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Stroka
              wrote on sidst redigeret af
              #52

              God morgen 🙂

              1 Reply Last reply
              0
              • B Offline
                B Offline
                bibob
                wrote on sidst redigeret af
                #53

                God morgen. 🙂

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #54

                  AACR
                  1761 / 6 - Tissue Factor expression is associated with B7-H4-mediated immune evasion in ovarian clear cell carcinoma and with response to tisotumab vedotin in preclinical models https://www.abstractsonline.com/pp8/#!/21436/presentation/4318

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #55

                    Trial Update from innovaTV 205/ENGOT-cx8/GOG-3024: Tisotumab Vedotin Combinations in Recurrent or Metastatic Cervical Cancer https://oncodaily.com/industry/innovatv-205-engot-cx8

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #56

                      ” Very happy to see ADCs finally moving earlier in cervical cancer — because in real life, using them late is often too late!!!
                      Recurrent/metastatic cervical cancer is still an unmet need. In daily practice, when we give Tisotumab Vedotin (TV) after immunotherapy, patients are often already compromised — fistulas, nephrostomies, frailty. That’s not when you unlock the full potential of an ADC.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #57

                        The 5-year innovaTV 205 data clearly show that TV-based combinations (triplet/quadruplet regimens) are active and durable, especially in 1L, with response rates up to ~66% and OS approaching 2+ years.
                        If we believe in these drugs, we should use them earlier — not as a last resort. This shift toward early lines is not just interesting. It’s necessary.”

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #58

                          Just a moment...

                          favicon

                          (www.fiercebiotech.com)

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #59

                            Good old MOR 202 still alive

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #60

                              Interessant fund Sukkeralf:-) Stadig stor værdi efter mange år.

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #61

                                makes you wonder if hexabody-cd38 really was completely without residual
                                value...

                                1 Reply Last reply
                                0
                                • SolsenS Offline
                                  SolsenS Offline
                                  Solsen
                                  wrote on sidst redigeret af
                                  #62

                                  You have a point !

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #63

                                    Lilly går all in i Myeloma med en M&A på et fase 1 stof med upfront på $3,25 https://www.morningstar.com/news/dow-jones/202604204694/eli-lilly-to-buy-kelonia-therapeutics-for-initial-325-billion-update

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #64

                                      Epcoritamab Plus Lenalidomide and Rituximab in Practice: A Focus on EPCORE FL-1 https://www.pharmacytimes.com/view/epcoritamab-plus-lenalidomide-and-rituximab-in-practice-a-focus-on-epcore-fl-1

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #65

                                        E L 17.47, it was a complete scandal that
                                        Genmab dropped it. Erzo-gate.

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #66

                                          3 år siden Genmab lavede aftalen med Argenx - mon vi snart hører om det fører til noget. Synes ikke ret mange af de samarbejder de laver har ført noget med sig. BioNTech samarbejdet givet en del kliniske kandidater, men ellers har de været sløjt.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper